Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 31, 2017 20:04 pm UTC| Business
KING OF PRUSSIA, Pa., May 31, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 22, 2017 and May 30,...
Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 31, 2017 20:04 pm UTC| Business
KING OF PRUSSIA, Pa., May 31, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that the independent Compensation Committee of the Board of Directors of the Company approved, effective as of May 22, 2017 and May 30,...
Iridium to Present at William Blair Growth Stock Conference
May 31, 2017 20:03 pm UTC| Business
MCLEAN, Va., May 31, 2017 -- Iridium Communications Inc. (Nasdaq:IRDM) (“Iridium”) today announced that Chief Executive Officer Matthew J. Desch is scheduled to speak at the William Blair Growth Stock Conference in...
Iridium to Present at William Blair Growth Stock Conference
May 31, 2017 20:03 pm UTC| Business
MCLEAN, Va., May 31, 2017 -- Iridium Communications Inc. (Nasdaq:IRDM) (“Iridium”) today announced that Chief Executive Officer Matthew J. Desch is scheduled to speak at the William Blair Growth Stock Conference in...
Iridium to Present at William Blair Growth Stock Conference
May 31, 2017 20:03 pm UTC| Business
MCLEAN, Va., May 31, 2017 -- Iridium Communications Inc. (Nasdaq:IRDM) (“Iridium”) today announced that Chief Executive Officer Matthew J. Desch is scheduled to speak at the William Blair Growth Stock Conference in...
Editas Medicine Names Andrew Hirsch to Board of Directors
May 31, 2017 20:02 pm UTC| Business
CAMBRIDGE, Mass., May 31, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors, effective immediately. Mr. Hirsch will...
Editas Medicine Names Andrew Hirsch to Board of Directors
May 31, 2017 20:02 pm UTC| Business
CAMBRIDGE, Mass., May 31, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors, effective immediately. Mr. Hirsch will...